MUC1 and ovarian carcinoma: Budiu et al (2011) found that increased serum MUC1 and high anti-MUC1 antibody levels are potential prognostic biomarkers for poor clinical response and reduced overall survival in platinum-resistant or platinum-refractory ovarian cancer [32].